Quantifying ligand bias at seven-transmembrane receptors.


Journal Article

Seven transmembrane receptors (7TMRs), commonly referred to as G protein-coupled receptors, form a large part of the "druggable" genome. 7TMRs can signal through parallel pathways simultaneously, such as through heterotrimeric G proteins from different families, or, as more recently appreciated, through the multifunctional adapters, β-arrestins. Biased agonists, which signal with different efficacies to a receptor's multiple downstream pathways, are useful tools for deconvoluting this signaling complexity. These compounds may also be of therapeutic use because they have distinct functional and therapeutic profiles from "balanced agonists." Although some methods have been proposed to identify biased ligands, no comparison of these methods applied to the same set of data has been performed. Therefore, at this time, there are no generally accepted methods to quantify the relative bias of different ligands, making studies of biased signaling difficult. Here, we use complementary computational approaches for the quantification of ligand bias and demonstrate their application to two well known drug targets, the β2 adrenergic and angiotensin II type 1A receptors. The strategy outlined here allows a quantification of ligand bias and the identification of weakly biased compounds. This general method should aid in deciphering complex signaling pathways and may be useful for the development of novel biased therapeutic ligands as drugs.

Full Text

Duke Authors

Cited Authors

  • Rajagopal, S; Ahn, S; Rominger, DH; Gowen-MacDonald, W; Lam, CM; Dewire, SM; Violin, JD; Lefkowitz, RJ

Published Date

  • September 2011

Published In

Volume / Issue

  • 80 / 3

Start / End Page

  • 367 - 377

PubMed ID

  • 21610196

Pubmed Central ID

  • 21610196

Electronic International Standard Serial Number (EISSN)

  • 1521-0111

Digital Object Identifier (DOI)

  • 10.1124/mol.111.072801


  • eng

Conference Location

  • United States